This HTML5 document contains 165 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n9http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q35170212
rdf:type
wikibase:Item
schema:description
мақолаи илмӣ wetenschappelijk artikel 2011年論文 artículu científicu espublizáu en 2011 vitenskapelig artikkel مقالة علمية 2011年论文 wissenschaftlicher Artikel научна статия научни чланак บทความทางวิทยาศาสตร์ teaduslik artikkel artigo científico (publicado na 2011) scienca artikolo artikulong pang-agham ২০১১-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ artículo científico publicado en 2011 tudományos cikk articolo scientifico bài báo khoa học vitskapeleg artikkel 2011년 논문 vedecký článok سائنسی مضمون 2011年论文 مقالهٔ علمی 2011年の論文 mokslinis straipsnis tieteellinen artikkeli наукова стаття, опублікована в червні 2011 article científic სამეცნიერო სტატია artigo científico (publicado na 2011) научная статья 2011年论文 מאמר מדעי article scientific vetenskaplig artikel 2011年論文 videnskabelig artikel (udgivet 2011) 2011 nî lūn-bûn scientific article vědecký článek мақолаи илмӣ 2011年論文 naučni članak επιστημονικό άρθρο научни чланак 2011年論文 2011 թվականի հունիսին հրատարակված գիտական հոդված 2011年论文 artigo científico bilimsel makale artykuł naukowy articol științific artikull shkencor 2011年论文 2011年論文 2011年论文 2011 թուականի Յունիսին հրատարակուած գիտական յօդուած article scientifique (publié 2011)
p:P577
wds:Q35170212-BD8F06B6-4877-4403-8974-A493D796596E
wdt:P577
2011-06-27T00:00:00Z
p:P407
wds:Q35170212-50D90FB1-5A66-4E4B-8DFE-3A9B328EF9A3
wdt:P407
wd:Q1860
p:P2860
wds:Q35170212-B9869342-DD4E-43BC-AD73-024FF0EAF8B7 wds:Q35170212-C6702525-A684-4800-9AF2-DCF19D064AD3 wds:Q35170212-CCC4299F-FE29-4868-AB03-87F06AFD71AC wds:Q35170212-8E4C5319-BE23-46CE-9C4B-819E970CD0A6 wds:Q35170212-97147268-47E5-44D4-9CC8-003C2C436151 wds:Q35170212-9D53C31C-ADAF-4A6F-9402-5D14D3CDE18C wds:Q35170212-B5499A5B-C9AB-45D5-94CB-576D6FAA6821 wds:Q35170212-75DC13EC-09C3-4A61-BF2D-AB6C49EB17CD wds:Q35170212-8565904B-D4B3-4061-B7E7-2AA0030BC2E6 wds:Q35170212-5CCA8315-BD84-4CD6-8A72-237BC9685B7A wds:Q35170212-69E40851-48E0-424E-A7BE-7CA908240800 wds:Q35170212-0643C1CA-9EA2-4801-B910-A23A1413C509 wds:Q35170212-09307C9E-61A0-4FC1-896A-BB59D6C6FDA1 wds:Q35170212-12A8CBC8-0D5F-4C8E-BBB3-776B3DBBD37B wds:Q35170212-16B472B8-0F2C-4EF7-9086-A0452C67ED35
wdt:P2860
wd:Q57758319 wd:Q37421104 wd:Q33383758 wd:Q33361488 wd:Q46604466 wd:Q80407725 wd:Q35669133 wd:Q67523718 wd:Q34557866 wd:Q29616236 wd:Q39076225 wd:Q29620070 wd:Q27851466 wd:Q33385281 wd:Q34049250
p:P2093
wds:Q35170212-86685315-E324-4372-AB6A-9EEA8A95D6E2 wds:Q35170212-77F8A682-8AFE-482B-BA9E-1D1AE5F37575 wds:Q35170212-6B4D1746-D70D-4C7C-886F-CD22E7BFAEB5 wds:Q35170212-6F3388D8-AC62-41E4-8D74-5D9C4ECA93A7 wds:Q35170212-011A5922-D66F-4F68-85A4-8F3A0489F613 wds:Q35170212-F186EB78-239E-42A6-91E4-D456674741AB wds:Q35170212-F8F2FF5C-D5D6-4368-A95A-E0A4202B5579 wds:Q35170212-BBD43949-ECDD-461F-A0D5-AF078F44A4CD wds:Q35170212-A77B2F97-D011-4908-A9CF-A4F5B57977B4 wds:Q35170212-9321B83B-786B-4F25-94A9-F38F01B60C68 wds:Q35170212-8A0B0D68-E4E2-40D9-B7AA-532B091BE5FB
wdt:P2093
Sunil Krishnan Waqar Haque Howard Safran Bridgett D Hobbs Christopher H Crane Gregg A Staerkel Robert A Wolff Jeffrey E Lee John S Yordy Milind M Javle Gauri R Varadhachary
rdfs:label
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression
skos:prefLabel
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression
schema:name
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression
p:P50
wds:Q35170212-4F5F3773-5F0B-4D2F-B20B-2710F918864E wds:Q35170212-EE89873B-173C-4C0A-AFDE-C6C3AA8DBC2B wds:Q35170212-F0D7C46A-51C9-4A47-B2FA-3FEAE113C0F4
wdt:P50
wd:Q96250261 wd:Q14947937 wd:Q107460126
p:P1476
wds:Q35170212-E9E24E56-C165-468D-929F-13A52CC065E4
wdt:P1476
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression
p:P304
wds:Q35170212-0022BC6D-627D-43E8-90FC-3668B15A7E4A
wdt:P304
3037-3043
p:P31
wds:Q35170212-27CE954B-7DF7-4BEF-B44A-5579D4D628D2
wdt:P31
wd:Q13442814
p:P921
wds:Q35170212-7608A06F-8DDC-476B-BBBF-E9C6131F17FA wds:Q35170212-25B179EB-A820-4ADC-818B-2918A9A63606 wds:Q35170212-08B54CE4-C0C0-450E-9347-EE4BFA43CD4A wds:Q35170212-5CDF468B-25C0-4ADF-97AF-4DB80B3807C4 wds:Q35170212-6927EA1D-3077-4E65-ACF9-0835155D8CD0 wds:Q35170212-3BA5F6D3-D4C8-421E-A8AB-13ED92B52BA5
wdt:P921
wd:Q18556189 wd:Q42824440 wd:Q5090613 wd:Q420296 wd:Q356033 wd:Q422327
p:P698
wds:Q35170212-77D345D8-378B-403C-8DAC-80F8621C5E7A
wdtn:P698
n11:21709185
wdt:P698
21709185
p:P1433
wds:Q35170212-E2580C30-52E3-46DE-BE3B-067349047AF6
wdt:P1433
wd:Q400292
p:P433
wds:Q35170212-B2B741F0-825B-4B84-80B7-B79D3DA2ED38
p:P478
wds:Q35170212-E6256E7C-55A0-4C1D-B29C-C8AB21DB2837
wdt:P433
22
wdt:P478
29
p:P356
wds:Q35170212-35129174-3F17-442E-BFE3-87E606F354E1
wdtn:P356
n9:JCO.2010.33.8038
wdt:P356
10.1200/JCO.2010.33.8038
p:P932
wds:Q35170212-37798358-70F9-46D5-BD6C-0E37EB4E3BC3
wdt:P932
3157965